(Q66852701)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1063907%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

title

Chemoimmunotherapy of human solid tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1063907%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

author name string

J. U. Gutterman

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1063907

18 August 2022

G. M. Mavligit

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1063907

18 August 2022

E. M. Hersh

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1063907

18 August 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1063907

18 August 2022

publication date

1 May 1976

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1063907%20AND%20SRC:MED&resulttype=core&format=json

Medical Clinics of North America

30 August 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1063907%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

volume

60

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1063907%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1063907%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

page(s)

441-462

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1063907%20AND%20SRC:MED&resulttype=core&format=json

Endotoxin and double stranded RNA render macrophages cytotoxic

30 August 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

An experimental model of active immunotherapy preceded by cytoreductive chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Factor time for active immunotherapy after cytoreductive chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

BCG immunotherapy of pulmonary growths from intravenously transferred rat tumour cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Host resistance and survival in carcinoma of breast: a study of 104 cases of medullary carcinoma in a series of 1,411 cases of breast cancer followed for 20 years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Immunological Effects of BCG in Malignant Melanoma: Two Modes of Administration Compared

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Brief communication: antigenic relationship between Mycobacterium bovis (BCG) and a guinea pig hepatoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Immunoelectronmicroscopic analysis of surface antigens common to Mycobacterium bovis (BCG) and tumor cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

An endotoxin-induced serum factor that causes necrosis of tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Patient survival after chemotherapy and its relationship to in vitro lymphocyte blastogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Amputation and Adriamycin in Primary Osteosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Active Immunotherapy with Corynebacterium parvum and Chemotherapy in Murine Fibrosarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Inhibition of tumor growth by recognition factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Methotrexate plus bacillus Calmette-Guérin (BCG) and isoniazid in the treatment of cancer of the head and neck

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Impaired immunologic reactivity and recurrence following cancer surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Cell-mediated immunity to human tumors. Abrogation by serum factors and nonspecific effects of oral BCG therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Inhibition of drug-metabolizing enzymes in the rat after Bacillus Calmette-Guérin treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Inhibitory effect of prolongedcorynebacterium parvum and cyclophosphamide administration on the growth of established tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Aerosol BCG treatment of carcinoma metastatic to the lung: A phase I study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Chemoimmunotherapy of Disseminated Malignant Melanoma with Dimethyl Triazeno Imidazole Carboxamide and Bacillus Calmette-Guérin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Active immunotherapy with B.C.G. for recurrent malignant melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Chemoimmunotherapy of adult acute leukaemia. Prolongation of remission in myeloblastic leukaemia with B.C.G.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Blocking of cell‐mediated tumor immunity by sera from patients with growing neoplasms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

[BCG-non specific immunotherapy of Hodgkin's disease. Preliminary results from a controlled investigation]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Daily intravenous infusions of Corynebacterium parvum in twenty patients with disseminated cancer: a preliminary report of clinical and biologic findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Potentiation of T-cell-mediated immunity by selective suppression of antibody formation with cyclophosphamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Immunopotentiation With BeG. I. Immune Response to Different Strains and Preparations2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Second-look operation for colon carcinoma after fluorouracil therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer of the Dukes' C classification. Preliminary clinical results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Immunotherapy: its possible application in the management of large-bowel cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Immunoprophylaxis and immunotherapy for a murine fibrosarcoma with C. granulosum and C. parvum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Shared antigens between Mycobacterium bovis (BCG) and neoplastic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

BCG immunotherapy of malignant melanoma: summary of a seven-year experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Effects of dialyzable transfer factor in patients with breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Lymphocyte cytotoxicity in bladder cancer. No requirement for thymus-derived effector cells?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Lymphoid cells mediating tumor-specific cytotoxicity to carcinoma of the urinary bladder. Separation of the effector population using a surface marker

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Malignant tumors arising de novo in immunosuppressed organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Cyclic AMP and immune responses: changes in the splenic level of cyclic AMP during the response of mice to antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Tumor regression caused by endotoxins and mycobacterial fractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Levamisole in advanced human breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Adjuvant chemotherapy with 5-fluorouracil in surgery for colorectal cancer: eight-year progress report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Immunoregulation, oncogenic viruses, and malignant lymphomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Delay in Progression of Malignant Lymphoma after BCG Vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Prevalence and prognosis of individual clinical and pathologic variables associated with colorectal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Adjuvant therapy of cancer via the cellular immune mechanism or fibrin by induced fibrinolysis and oral anticoagulants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

Respiratory and systemic cellular and humoral immune responses to influenza virus vaccine administered parenterally or by nose drops

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2931891-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-7125(16)31891-0

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1063907%20AND%20SRC:MED&resulttype=core&format=json

30 August 2019

1 reference